

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM358075

| | | | |
|--|-------------------------------|-----------------------|--------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | RELEASE OF SECURITY INTEREST | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| Wilmington Trust, National Association | | 09/16/2013 | CORPORATION: |
| RECEIVING PARTY DATA | | | |
| Name: | DRUGTECH CORPORATION | | |
| Doing Business As: | Lumara Health IP Ltd. | | |
| Street Address: | 16640 Chesterfield Grove Road | | |
| Internal Address: | Suite 200 | | |
| City: | Chesterfield | | |
| State/Country: | MISSOURI | | |
| Postal Code: | 63005 | | |
| Entity Type: | CORPORATION: DELAWARE | | |
| PROPERTY NUMBERS Total: 41 | | | |
| Property Type | Number | Word Mark | |
| Registration Number: | 2517899 | CALCIPURE | |
| Registration Number: | 1156939 | CHROMAGEN | |
| Registration Number: | 3395236 | CHRONOMETRIC SYSTEM | |
| Registration Number: | 3184560 | CLINDESSE | |
| Registration Number: | 2948258 | CONTINUUM OF CARE | |
| Registration Number: | 3111521 | ENCORA | |
| Registration Number: | 3688522 | EVAMIST | |
| Registration Number: | 3550530 | EVAMIST | |
| Registration Number: | 1997221 | FLAVORTECH | |
| Registration Number: | 1912198 | GUAIFENEX | |
| Registration Number: | 2457708 | GYNAZOLE 1 | |
| Registration Number: | 2031080 | HISTA-VENT | |
| Registration Number: | 1932221 | HISTINEX | |
| Registration Number: | 4317346 | KV PHARMACEUTICAL | |
| Registration Number: | 1293848 | METER RELEASE | |
| Registration Number: | 1939204 | MICRO RELEASE | |
| Registration Number: | 2031082 | NATALCARE | |
| TRADEMARK | | | |

OP \$1040.00 2517899

| Property Type | Number | Word Mark |
|----------------------|----------|---------------------------------------|
| Registration Number: | 804556 | NIFEREX |
| Registration Number: | 3291637 | NIFEREX GOLD |
| Registration Number: | 2441392 | NUTRINATE |
| Registration Number: | 2940425 | OMEGANATE |
| Registration Number: | 2719613 | PRE CARE CONCEIVE |
| Registration Number: | 1365182 | PRECARE |
| Registration Number: | 3320970 | PRECARE PREMIER |
| Registration Number: | 2582817 | PRIMACARE |
| Registration Number: | 3643470 | PRIMACARE ADVANTAGE |
| Registration Number: | 3414475 | PRIMACARE ONE |
| Registration Number: | 3406639 | REPLIVA |
| Registration Number: | 3389789 | REPLIVA 21/7 |
| Registration Number: | 1192702 | SITE RELEASE |
| Registration Number: | 2742749 | STRONGSTART |
| Registration Number: | 4254188 | THER-RX |
| Registration Number: | 2948813 | THE THER-RX CONTINUUM OF WOMEN'S CARE |
| Serial Number: | 77558671 | KV |
| Serial Number: | 77558677 | KV PHARMACEUTICAL |
| Serial Number: | 77519812 | EVAMIST |
| Serial Number: | 77558690 | KV |
| Serial Number: | 77558695 | KV PHARMACEUTICAL |
| Serial Number: | 77558703 | KV PHARMACEUTICAL |
| Serial Number: | 77466451 | LIQUETTE |
| Serial Number: | 77885809 | PREMESISRX |

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: PeterHart@goodwinprocter.com

Correspondent Name: GOODWIN PROCTER LLP C/O PETER HART

Address Line 1: THE NEW YORK TIMES BUILDING

Address Line 2: 620 EIGHTH AVENUE

Address Line 4: NEW YORK, NEW YORK 10018

NAME OF SUBMITTER: Peter Hart

SIGNATURE: /Peter Hart/

DATE SIGNED: 10/09/2015

Total Attachments: 5

source=25. WTC Trademark Release#page1.tif

source=25. WTC Trademark Release#page2.tif

source=25. WTC Trademark Release#page3.tif

source=25. WTC Trademark Release#page4.tif

source=25. WTC Trademark Release#page5.tif

RELEASE OF SECURITY INTEREST IN TRADEMARKS

THIS RELEASE OF SECURITY INTEREST IN TRADEMARKS (the "Release"), is granted and conveyed as of this 16 day of September, 2013, by Wilmington Trust, National Association (successor by merger to Wilmington Trust FSB), as collateral agent (the "Agent"), in favor of DrugTech Corporation, a Delaware corporation (the "Obligor").

WITNESSETH:

WHEREAS, pursuant to that certain Pledge and Security Agreement, dated as of March 17, 2011, by and among the parties and the other grantors party thereto (the "Security Agreement"), the Obligor granted to the Agent security interests in certain collateral, including the Trademark Collateral (as hereinafter defined);

WHEREAS, in connection with the Security Agreement, the Obligor executed that certain Trademark Security Agreement, dated as of March 17, 2011 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Trademark Security Agreement"), under which the Obligor mortgaged, pledged and granted to the Agent a lien on, and security interest in and to, all of Obligor's right, title and interest in, to and under the Trademark Collateral (together with the security interests granted pursuant to the Security Agreement, the "Security Interests"), for recording with the United States Patent and Trademark Office and any other appropriate governmental authorities;

WHEREAS, the Trademark Security Agreement was recorded in the United States Patent and Trademark Office on March 18, 2011 at Reel 4501/Frame 0167;

WHEREAS, pursuant to that certain Order Confirming Sixth Amended Joint Chapter 11 Plan of Reorganization for K-V Discovery Solutions, Inc. and its Affiliated Debtors (the "Order"), entered in the United States Bankruptcy Court, Southern District of New York on August 29, 2013 in connection with the Sixth Amended Joint Chapter 11 Plan of Reorganization of K-V Discovery Solutions and its Affiliated Debtors, dated July 17, 2013 (the "Plan"), the Obligor and Agent are authorized, upon the Effective Date (as defined in the Plan), to: (a) terminate and release all liens and interests of the Agent in the Trademark Collateral and (b) execute and deliver evidence of such termination and release for filing in the United States Patent and Trademark Office;

WHEREAS, all conditions to the occurrence of the Effective Date (as defined in the Plan) have occurred and the Effective Date (as defined in the Plan) is the same as the date of this Release; and

WHEREAS, all conditions to the release of the Agent's Security Interests in the Trademark Collateral have been satisfied, and the parties seek to make record of the Agent's release to the Obligor of any and all of its Security Interests in the Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Definitions. All capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Security Agreement. The term “Trademark Collateral,” as used herein, shall mean (a) all of the Obligor’s right, title and interest in and to the trademarks, trademark registrations, and trademark applications listed on Schedule A hereto, and all of the goodwill of the business connected with the use of, and symbolized by, each such trademark, trademark registration and trademark application; (b) all renewals of the foregoing; and (c) all proceeds of the foregoing, including without limitation any claim against third parties for damages by reason of past, present or future infringement or dilution of any trademark, trademark registration, or trademark application listed on Schedule A hereto or by reason of injury to the goodwill associated with any such trademark, trademark registration, or trademark application, in each case together with the right to sue for and collect said damages.

2. Release of Security Interests. The Agent hereby terminates, discharges and releases to the Obligor the Security Interests in the Trademark Collateral, and any right, title or interest of the Agent in such Trademark Collateral shall hereby cease and become void.


3. Further Assurances. The Agent hereby agrees to duly execute, acknowledge, procure and deliver, at the sole expense of the Obligor or its successors and assigns, any further documents and to do such other acts as may be reasonably necessary to effect the termination, release, discharge or reassignment to the Obligor of the Security Interests contemplated hereby.

4. Governing Law. This Release shall be governed by, and construed in accordance with, the laws of the State of New York.

[signature page follows]

IN WITNESS WHEREOF, the Agent has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

WILMINGTON TRUST, NATIONAL
ASSOCIATION (successor by merger to
Wilmington Trust FSB), as Agent

By: 
Name: Peter Finkert
Title: V. P.

[Signature Page to Release of Security Interest in Trademarks]

SCHEDULE A**TRADEMARKS**

| Trademark | Registration No. | Registration Date | Owner |
|------------------------------|-------------------------|--------------------------|----------------------|
| CALCIPURE | 2,517,899 | 12/11/2001 | Drugtech Corporation |
| CHROMAGEN | 1,156,939 | 6/9/1981 | |
| CHRONOMETRIC SYSTEM | 3,395,236 | 3/11/2008 | Drugtech Corporation |
| CLINDESSE | 3,184,560 | 12/12/2006 | Drugtech Corporation |
| CONTINUUM OF CARE | 2,948,258 | 5/10/2005 | Drugtech Corporation |
| ENCORA | 3,111,521 | 7/4/2006 | Drugtech Corporation |
| EVAMIST and Design | 3,688,522 | 9/29/2009 | Drugtech Corporation |
| EVAMIST | 3,550,530 | 12/23/2008 | Drugtech Corporation |
| FLAVORTECH (Stylized) | 1,997,221 | 8/27/1996 | Drugtech Corporation |
| GUAIFENEX | 1,912,198 | 8/15/1995 | Drugtech Corporation |
| GYNAZOLE 1 | 2,457,708 | 6/5/2001 | Drugtech Corporation |
| HISTA-VENT | 2,031,080 | 1/14/1997 | Drugtech Corporation |
| HISTINEX | 1,932,221 | 10/31/1995 | Drugtech Corporation |
| KV PHARMACEUTICAL and Design | 4,317,346 | 4/9/2013 | Drugtech Corporation |
| METER RELEASE | 1,293,848 | 9/11/1984 | Drugtech Corporation |
| MICRO RELEASE | 1,939,204 | 12/5/1995 | Drugtech Corporation |
| NATALCARE | 2,031,082 | 1/14/1997 | Drugtech Corporation |
| NIFEREX (Stylized) | 804,556 | 3/1/1966 | Drugtech Corporation |
| NIFEREX GOLD | 3,291,637 | 9/11/2007 | Drugtech Corporation |
| NUTRINATE | 2,441,392 | 4/3/2001 | Drugtech Corporation |

| | | | |
|---|-----------|------------|----------------------|
| OMEGANATE | 2,940,425 | 4/12/2005 | Drugtech Corporation |
| PRE CARE CONCEIVE | 2,719,613 | 5/27/2003 | Drugtech Corporation |
| PRECARE | 1,365,182 | 10/15/1985 | Drugtech Corporation |
| PRECARE PREMIER | 3,320,970 | 10/23/2007 | Drugtech Corporation |
| PRIMACARE | 2,582,817 | 6/18/2002 | Drugtech Corporation |
| PRIMACARE ADVANTAGE | 3,643,470 | 6/23/2009 | Drugtech Corporation |
| PRIMACARE ONE | 3,414,475 | 4/22/2008 | Drugtech Corporation |
| REPLIVA | 3,406,639 | 4/1/2008 | Drugtech Corporation |
| REPLIVA 21/7 | 3,389,789 | 2/26/2008 | Drugtech Corporation |
| SITE RELEASE | 1,192,702 | 3/30/1982 | Drugtech Corporation |
| STRONGSTART | 2,742,749 | 7/29/2003 | Drugtech Corporation |
| THER-RX | 4,254,188 | 12/4/2012 | Drugtech Corporation |
| THE THE-RX CONTINUUM OF WOMEN'S CARE and Design | 2,948,813 | 5/10/2005 | Drugtech Corporation |

U.S. Trademark Applications

| Trademark | Application No. | Application Date | Owner |
|-------------------|------------------------|-------------------------|----------------------|
| KV | 77/558,671 | 8/29/2008 | Drugtech Corporation |
| KV PHARMACEUTICAL | 77/558,677 | 8/29/2008 | Drugtech Corporation |
| EVAMIST | 77/519,812 | 7/10/2008 | Drugtech Corporation |
| KV | 77/558,690 | 8/29/2008 | Drugtech Corporation |
| KV PHARMACEUTICAL | 77/558,695 | 8/29/2008 | Drugtech Corporation |
| KV PHARMACEUTICAL | 77/558,703 | 8/29/2008 | Drugtech Corporation |
| LIQUETTE | 77/466,451 | 5/6/2008 | Drugtech Corporation |
| PREMESISRX | 77/885,809 | 12/3/2009 | Drugtech Corporation |